NEW YORK, August 24, 2022 /PRNewswire/ — GLO Pharma, Inc., the parent company of breakthrough subdermal skin care brand Ourself, today announces the appointment of Brent Saunders on its Board of Directors. Mr. Saunders, who currently serves as Executive Chairman of The Beauty Health Company, will join the board effective immediately. His appointment adds a new seat to GLO Pharma’s board, which now consists of six members and is led by the Chairman Scott L. Glenn.
Mr. Saunders is a respected innovator who brings to the Board his extensive leadership experience in the biopharma and medical aesthetics sectors, having led several mergers and acquisitions and served in numerous leadership roles at prominent global pharmaceutical and of health care.
from July 2020 to May 2021, Mr. Sauders served as President, Chief Executive Officer and Chairman of the Board of Directors of Vesper Healthcare Acquisition Corp. (“Vesper”), and led Vesper’s merger with The HydraFacial Company to become Beauty Health Company, of which he continues to serve as Executive Chairman. Previously, he served as CEO and President of Allergan plc (“Allergan”), best known as the maker of Botox, from July 2014 to May 2020and was instrumental in leading the acquisition of Allergan by AbbVie, Inc. He also served on the board of Allergan July 2014 to May 2020and as its Chairman from October 2016 to May 2020.
Mr. Saunders previously served as Chief Executive Officer and President of Forest Laboratories, Inc. (“Forest”), and later as CEO of the pharmaceutical company Actavis, after that company acquired Forest. Later, Saunders negotiated Actavis’ merger with Allergan, which closed on 70.5 billion dollars. Mr. Saunders also held the role of Chief Executive Officer of Bausch + Lomb Incorporated, a leading global eye health company, where he oversaw the company’s acquisition by Valeant Pharmaceuticals in 2013. From 2003 to 2010, he held numerous leadership positions at Schering -Plow Corporation, where he led the company’s merger with Merck & Co and the acquisition of Organon BioSciences. He is the founder of SPAC Vesper Healthcare Acquisition, and also currently serves on the boards of directors of BridgeBio Pharma, Inc. and Cisco (NASDAQ: CSCO ).
“Mr. Saunders’ experience scaling and transforming biopharma and medical aesthetics businesses, first with Allergan and now with The Beauty Health Company, makes him an invaluable asset to the GLO Pharma Board,” says the Chairman. Scott Glenn. “As we build the product offering of our consumer brand Yourself and a roadmap of current alternatives to medical procedures, Brent brings incredible insight to the conversation, especially as we develop new innovations in the wrinkle relaxer category in the near future.”
This appointment follows the recent announcement of Rothy’s CFO Dayna Quanbeck to the Board of GLO Pharma and the launch of GLO Pharma’s first consumer brand, Ourself, in February 2022. We ourselves are supported by 40 million dollars in funding to date from investors including Lightspeed Venture Partners, First Round Capital and Mr. Glenn.
Factory PR // Liz Hill
About GLO Pharma:
GLO Pharma is a biotechnology company dedicated to the development of innovative approaches to beauty and aesthetics. It was founded in 2018 by Scott Glenn and Lauren Otsuki, innovators in the biotech space for more than 20 years. Mr. Glenn and Mrs. Otsuki previously founded and developed the professional skin care companies Alastin Skincare and SkinMedica, along with numerous pharmaceutical companies aimed at solving some of the most difficult medical issues in infertility, diabetes, cardiovascular disease and cancer. In 2022, GLO Pharma launched its first consumer brand, Ourself, as the first Subtopical Skincare™™ System, bridging the gap between traditional skin care products and clinical procedures through the use of biotechnology.
View original content to download multimedia: https://www.prnewswire.com/news-releases/glo-pharma-appoints-current-executive-chairman-of-the-beauty-health-company-and-former-allergan- plc -ceo-brent-saunders-to-its-board-of-directors-301611368.html
SOURCE GLO Pharma